More information: Yi-Zong Lee et al, Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory ...

“This first-in-human study of EDP-323, our selective, direct-acting antiviral specifically targeting the RSV L-protein, is an important milestone for Enanta as we mark the continued expansion of ...

In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses ...

Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation.

Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation.

Figure 1. (Left) Pre- and (Right) Post-fusion forms of the RSV F protein. Protein structural arrangement occurs during the host-virus membrane fusion, signaling viral infection. 5 Image Credit ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Zhu reengineered the RSV F protein by changing a pair of molecules at its center, ... Han J, Zhang YN, et al. Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory ...

Detailed price information for Enanta Pharmaceutica (ENTA-Q) from The Globe and Mail including charting and trades.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral ...